Arriving in the landscape of excess body fat treatment, retatrutide presents a distinct strategy. Beyond many existing medications, retatrutide operates as a dual agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. This dual stimulation encourages various beneficia